Skip to Content

'
Powel H. Brown, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor and Chairman, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1360
Houston, TX 77030
Room Number: CPB6.3468
Phone: 713-745-3672
Fax: 713-794-4679
Email: phbrown@mdanderson.org

Education & Training

Degree-Granting Education

1985 New York University, New York, NY, MD, Medicine
1984 New York University, New York, NY, PHD, Immunology
1979 University of North Carolina, Chapel Hill, NC, BS, Chemistry

Experience/Service

Academic Appointments

Assistant Professor, Medicine, Medical Oncology, The University of Texas Health Science Center at San Antonio, Texas, San Antonio, TX, 11/1995-3/1998
Senior Staff Scientist, Biomarkers Prevention Research Branch, National Cancer Institute, National Institute of Health, Bethesda, MD, 7/1991-11/1995

Honors and Awards

2009-present John Charles Cain Distinguished Endowed Chair, University of Texas MD Anderson Cancer Center

Selected Publications

Peer-Reviewed Original Research Articles
1. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH. Estrogen Induces c-myc Gene Expression via an Upstream Enhancer Activated by the Estrogen Receptor and the AP-1 Transcription Factor. Mol Endocrinol 25(9):1527-38, 9/2011. e-Pub 8/2011. PMCID: PMC3165912.
2. Cuzick J, Decensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12(5):496-503, 2011. PMID: 21441069.
3. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12(3). e-Pub 6/2010. PMCID: PMC2917035.
4. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst 101(2):107-13, 2009. PMCID: PMC2639315.
5. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown PH. Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer. Clin Cancer Res 15(20):6327-40, 2009. PMCID: PMC2763053.
6. Chen L, Krisko TI, Speers CW, Reif D, Brown PH. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Research 1:69(23):8853-61, 2009. PMCID: PMC2830975.
7. Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, Brown PH. Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 284(1):345-53, 2009. PMCID: PMC2610495.
8. Brown PH, Subbaramaiah K, Salmon AP, Baker R, Newman RA, Yang P, Zhou XK, Bissonnette RP, Dannenberg AJ, Howe LR. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila Pa) 1(3):208-14, 2008. PMCID: PMC2612594.
9. DeNardo DG, Cuba VL, Kim H, Wu K, Lee AV, Brown PH. Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol 277(1-2):13-25, 2007. PMID: 17825481.
10. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76, 2007. PMCID: PMC1929138.
11. Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res 66(24):12009-18, 2006. PMID: 17178900.
12. Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim HT, Brown PH, Sporn MB. The combination of the rexinoid, LG100268, and a SERM, either Arzoxifene or Acolbifene, synergize in the prevention and treatment of mammary tumors in an estrogen receptor negative model of breast cancer. Clinical Cancer Research 12(19):5902-9, 2006.
13. DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol 19(2):362-78, 2005. PMID: 15514030.
14. Kong G, Kim HT, Wu K, DeNardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res 65(8):3462-9, 2005. PMID: 15833882.
15. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62(22):6376-80, 2002. PMID: 12438218.

Grant & Contract Support

Title: Cancer Prevention Committee Co-Chair
Funding Source: Southwest Oncology Group (SWOG)
Role: Principal Investigator
Duration: 6/1/2012 - 5/31/2017
 
Title: Phase I and Phase II Clinical Trials of Cancer Chemopreventive Agents
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/30/2003 - 9/29/2014

Last updated: 2/25/2013